Climb Bio, Inc. (CLYM): Total Liabilities
$7.27M
As of 2025-12-31
$6.75M
As of 2026-06-30
+5.0%
3-year compound annual growth
+18.9%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.27M | +37.0% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $5.31M | +84.9% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $2.87M | -54.3% | 2025-03-25, Balance as of period end |
| 2022-12-31 | $6.28M | +4.0% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $6.04M | +97.1% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $3.06M | n/a | 2022-03-07, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | 2025-12-31 | $7.27M | +37.0% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 2025-12-31 | $20.69M | +53.8% |
| Eledon Pharmaceuticals, Inc. (ELDN) | 2025-12-31 | $32.23M | -45.6% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $23.85M | -11.7% |
| Apimeds Pharmaceuticals US, Inc. (APUS) | 2025-12-31 | $10.84M | +690.3% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $295.01M | +3.2% |
| Cypherpunk Technologies Inc. (CYPH) | 2025-12-31 | $9.68M | -31.3% |
| Transcode Therapeutics, Inc. (RNAZ) | 2025-12-31 | $10.52M | +12.9% |
| PepGen Inc. (PEPG) | 2025-12-31 | $26.46M | -18.0% |
Compare CLYM, CRBP, ELDN, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗